Patent classifications
C07D223/12
Phenyl amino piperidine mTORC inhibitors and uses thereof
The present invention provides compounds, compositions thereof, and methods of using the same.
Phenyl amino piperidine mTORC inhibitors and uses thereof
The present invention provides compounds, compositions thereof, and methods of using the same.
FPR2 (FORMYL PEPTIDE RECEPTOR 2)RECEPTOR AGONISTS AND THEIR USE IN THE TREATMENT OF THE AUTISM SPECTRUM DISORDER
The present invention relates to novel Formyl Peptide Receptor subtype 2 (FPR2) agonist compounds and their use in the recovery of the inflammatory phenomena in which said receptor is involved, particularly in the context of the treatment of the autism spectrum disorder.
FPR2 (FORMYL PEPTIDE RECEPTOR 2)RECEPTOR AGONISTS AND THEIR USE IN THE TREATMENT OF THE AUTISM SPECTRUM DISORDER
The present invention relates to novel Formyl Peptide Receptor subtype 2 (FPR2) agonist compounds and their use in the recovery of the inflammatory phenomena in which said receptor is involved, particularly in the context of the treatment of the autism spectrum disorder.
CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF
The present technology relates to cyclic keto-amide compounds of general formulae I to XXXII, compositions and kits thereof as calpain modulators and methods useful for the treatment of various diseases or disorders such as fibrotic disease or cancer which are associated or mediated, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is also applicable to cyclic keto-amide compounds which inhibit myofibroblast differentiation.
CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF
The present technology relates to cyclic keto-amide compounds of general formulae I to XXXII, compositions and kits thereof as calpain modulators and methods useful for the treatment of various diseases or disorders such as fibrotic disease or cancer which are associated or mediated, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is also applicable to cyclic keto-amide compounds which inhibit myofibroblast differentiation.
(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. ##STR00001##
(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. ##STR00001##
Histone deacetylase inhibitors
Provided herein are compounds and methods for inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
Histone deacetylase inhibitors
Provided herein are compounds and methods for inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).